Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

FDA Contradicts AAM's Generic Market Consolidation Argument

Nov 21 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Generic Manufacturers Try To Up Their Game As US Pressure Persists

Jun 16 2017

There's The Bolus! ANDA Sponsors Race To Avoid User Fee Spike

Oct 10 2017

Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

Aug 28 2017

ANDA Approvals Break Record, May Set New Normal

Jul 11 2017

Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?

Apr 11 2017

Q&A With US FDA Commissioner Scott Gottlieb

Nov 09 2017

Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition

Nov 09 2017

GDUFA: FDA Struggles Under Higher-Than-Expected Submission Volume

Mar 03 2014

Generic User Fee 'Relief' For Small Firms Would Mean Bigger Bills For Large One

Jan 26 2016

Additional Topics

United States FDA Generic Drugs Regulation Review Pathway BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window